Jean Jacques Bienaime
Chief Executive Officer at BioMarin Pharmaceutical Inc. · b. 1953
Sits on 5 boards. Overboarded · 5 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 5
- Current seats
- 5
- Board service
- 13 years
- Director since
- 2023
13 years of board service in total across 5 boards, counting each seat separately. Longest: BioMarin Pharmaceutical Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Immunome Inc. June 10, 202576.6%
-
Incyte Corp. June 10, 202594.7%
-
Incyte Corp. June 12, 202494.7%
-
Incyte Corp. June 14, 202394.6%
-
BioMarin Pharmaceutical Inc. May 23, 202391.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 17, 2026 | Keros Therapeutics Inc. | Open-market purchase | +1,000 | $10.27 | $10,270 |
| Aug 14, 2026 | Ascendis Pharma A/S | Open-market purchase | +1,100 | $245.85 | $270,435 |
| Aug 14, 2026 | Ascendis Pharma A/S | Open-market purchase | +900 | $246.91 | $222,219 |
| Jul 15, 2026 | Keros Therapeutics Inc. | Open-market purchase | +1,000 | $10.61 | $10,610 |
| Jun 15, 2026 | Keros Therapeutics Inc. | Open-market purchase | +1,000 | $10.19 | $10,190 |
| Jun 8, 2026 | Incyte Corp. | Grant or award | +1,642 | — | — |
| Jun 5, 2026 | Immunome Inc. | Open-market sale | −500 | $19.44 | $9,720 |
| Jun 5, 2026 | Immunome Inc. | Open-market sale | −10,000 | $19.41 | $194,100 |
| Jun 5, 2026 | Immunome Inc. | Open-market purchase | +6,000 | $19.48 | $116,880 |
| Jun 5, 2026 | Immunome Inc. | Open-market purchase | +3,500 | $19.46 | $68,110 |
| Jun 5, 2026 | Immunome Inc. | Open-market purchase | +1,000 | $19.27 | $19,270 |
| Jun 3, 2026 | Keros Therapeutics Inc. | Grant or award | +7,142 | — | — |
| May 29, 2026 | Ascendis Pharma A/S | Open-market purchase | +200 | $223.76 | $44,752 |
| May 29, 2026 | Ascendis Pharma A/S | Open-market purchase | +200 | $222.30 | $44,460 |
| May 29, 2026 | Ascendis Pharma A/S | Open-market purchase | +100 | $223.50 | $22,350 |
Questions about Jean Jacques Bienaime
What boards is Jean Jacques Bienaime on?
Jean Jacques Bienaime sits on the boards of Ascendis Pharma A/S, BioMarin Pharmaceutical Inc., Immunome Inc., Incyte Corp. and Keros Therapeutics Inc.
Has Jean Jacques Bienaime been a CEO?
Yes — Jean Jacques Bienaime was CEO of BioMarin Pharmaceutical Inc. (2005 – 2023).
How long has Jean Jacques Bienaime served on boards?
Our records show at least 13 years of board service across 5 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.